One key factor, perhaps overlooked, is AstraZeneca’s substantial base of nearly 170,000 Swedish shareholders, as shown in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback